HALLANDALE BEACH, FL--(Marketwired - November 13, 2013) - AllaChem, LLC announced today a successful completion of phase 1 clinical study with AV4025, a proprietary orally-bioavailable small molecule that blocks HCV genome replication by targeting viral non-structural protein NS5A. A double-blind, placebo-controlled, single ascending oral dose study with AV4025 showed safety and tolerability in healthy volunteers. Each dose cohort (10 subjects per cohort) received a single dose of 10, 20, or 40 mg of AV4025, or placebo (drug: placebo ratio 4:1). The drug was safe, well-tolerated; and no significant adverse events (SAE) were reported. The pharmacokinetic analyses demonstrated high and dose-dependent drug exposure in plasma, as well as long half-elimination time, supportive of once daily dosing.
Prof. Alexander Ivachtchenko, AllaChem’s CEO, stated: “We are very pleased with the safety and pharmacokinetic profiles of AV4025 in this first-in-man study. Further clinical study with AV4025 is scheduled to begin in the HCV patients in Q1 of 2014.”
Help employers find you! Check out all the jobs and post your resume.
